Polypharmacy and its association with dementia, Parkinson’s disease, and mortality risk in UK adults: a multistate modeling approach
Weiss J, Beydoun M, Georgescu M, Maldonado A, Beydoun H, Noren Hooten N, Tsai J, Song M, Nieva A, Evans M, Zonderman A. Polypharmacy and its association with dementia, Parkinson’s disease, and mortality risk in UK adults: a multistate modeling approach. GeroScience 2025, 47: 4349-4367. PMID: 40080299, PMCID: PMC12181516, DOI: 10.1007/s11357-025-01586-w.Peer-Reviewed Original ResearchConceptsHealth transitionOlder adultsCardiovascular healthLatent class analysisUK Biobank participantsRisks associated with polypharmacyHealth statesAssociated with dementiaPopulation-based cohortAssociated with higher riskYears of follow-upMedication combinationsClass analysisBiobank participantsHealth outcomesPolypharmacy statusPolypharmacy prevalenceSocioeconomic statusUK adultsMortality riskDementiaParkinson's diseasePolypharmacyHealthAdverse outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply